Cargando…
COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group
In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization,...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255352/ https://www.ncbi.nlm.nih.gov/pubmed/34212542 http://dx.doi.org/10.4168/aair.2021.13.4.526 |
_version_ | 1783717885120610304 |
---|---|
author | Kim, Mi-Ae Lee, Yong Won Kim, So Ri Kim, Joo-Hee Min, Taek ki Park, Hae-Sim Shin, Meeyong Ye, Young-Min Lee, Sooyoung Lee, Jeongmin Choi, Jeong-Hee Jang, Gwang Cheon Chang, Yoon-Seok |
author_facet | Kim, Mi-Ae Lee, Yong Won Kim, So Ri Kim, Joo-Hee Min, Taek ki Park, Hae-Sim Shin, Meeyong Ye, Young-Min Lee, Sooyoung Lee, Jeongmin Choi, Jeong-Hee Jang, Gwang Cheon Chang, Yoon-Seok |
author_sort | Kim, Mi-Ae |
collection | PubMed |
description | In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization, and the majority of AEFIs are caused by protective immune responses stimulated by vaccines. Most of the reported AEFIs are not serious, and many are not immunologically mediated or even reproducible on re-exposure. However, uncommon severe allergic adverse reactions, such as anaphylaxis or other allergic reactions, can occur after vaccinations. Confirmed allergic reactions to vaccines may be caused by residual non-human protein, preservatives, or stabilizers in the vaccine formulation (also known as excipients). There are 2 main potential allergenic/immunogenic excipients in COVID-19 vaccines, polyethylene glycol (PEG) and polysorbate 80. PEG, also known as macrogol, is an ingredient in various laxatives and injectable formulations, such as depot steroids. Polysorbate 80 is present in various medical products, creams, ointments, lotions, and medication tablets. Contraindications to the administration of COVID-19 vaccines include a previous history of severe allergic reactions to the first dose of COVID-19 vaccine or proven hypersensitivity to a vaccine component, such as PEG or polysorbate 80. Anaphylaxis or other allergic reactions following immunization can cause fear and loss of confidence in the safety of vaccines among the public. A better understanding of these events is thought to help alleviate concerns about the current COVID-19 vaccines and provide reassurance to the general population by analyzing the exact incidence of anaphylaxis and potential risk factors. COVID-19 vaccine-associated anaphylaxis could be prevented and managed by risk stratification based on our local and global experience. |
format | Online Article Text |
id | pubmed-8255352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-82553522021-07-06 COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group Kim, Mi-Ae Lee, Yong Won Kim, So Ri Kim, Joo-Hee Min, Taek ki Park, Hae-Sim Shin, Meeyong Ye, Young-Min Lee, Sooyoung Lee, Jeongmin Choi, Jeong-Hee Jang, Gwang Cheon Chang, Yoon-Seok Allergy Asthma Immunol Res Review In the era of novel coronavirus epidemics, vaccines against coronavirus disease 2019 (COVID-19) have been recognized as the most effective public health interventions to control the pandemic. An adverse event following immunization (AEFI) is defined as any untoward occurrence following immunization, and the majority of AEFIs are caused by protective immune responses stimulated by vaccines. Most of the reported AEFIs are not serious, and many are not immunologically mediated or even reproducible on re-exposure. However, uncommon severe allergic adverse reactions, such as anaphylaxis or other allergic reactions, can occur after vaccinations. Confirmed allergic reactions to vaccines may be caused by residual non-human protein, preservatives, or stabilizers in the vaccine formulation (also known as excipients). There are 2 main potential allergenic/immunogenic excipients in COVID-19 vaccines, polyethylene glycol (PEG) and polysorbate 80. PEG, also known as macrogol, is an ingredient in various laxatives and injectable formulations, such as depot steroids. Polysorbate 80 is present in various medical products, creams, ointments, lotions, and medication tablets. Contraindications to the administration of COVID-19 vaccines include a previous history of severe allergic reactions to the first dose of COVID-19 vaccine or proven hypersensitivity to a vaccine component, such as PEG or polysorbate 80. Anaphylaxis or other allergic reactions following immunization can cause fear and loss of confidence in the safety of vaccines among the public. A better understanding of these events is thought to help alleviate concerns about the current COVID-19 vaccines and provide reassurance to the general population by analyzing the exact incidence of anaphylaxis and potential risk factors. COVID-19 vaccine-associated anaphylaxis could be prevented and managed by risk stratification based on our local and global experience. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2021-06-21 /pmc/articles/PMC8255352/ /pubmed/34212542 http://dx.doi.org/10.4168/aair.2021.13.4.526 Text en Copyright © 2021 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Kim, Mi-Ae Lee, Yong Won Kim, So Ri Kim, Joo-Hee Min, Taek ki Park, Hae-Sim Shin, Meeyong Ye, Young-Min Lee, Sooyoung Lee, Jeongmin Choi, Jeong-Hee Jang, Gwang Cheon Chang, Yoon-Seok COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group |
title | COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group |
title_full | COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group |
title_fullStr | COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group |
title_full_unstemmed | COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group |
title_short | COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group |
title_sort | covid-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the kaaaci urticaria/angioedema/anaphylaxis working group |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255352/ https://www.ncbi.nlm.nih.gov/pubmed/34212542 http://dx.doi.org/10.4168/aair.2021.13.4.526 |
work_keys_str_mv | AT kimmiae covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT leeyongwon covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT kimsori covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT kimjoohee covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT mintaekki covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT parkhaesim covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT shinmeeyong covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT yeyoungmin covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT leesooyoung covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT leejeongmin covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT choijeonghee covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT janggwangcheon covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup AT changyoonseok covid19vaccineassociatedanaphylaxisandallergicreactionsconsensusstatementsofthekaaaciurticariaangioedemaanaphylaxisworkinggroup |